EGFR and non-small cell lung carcinoma: Analysis of 16 NSCLC patients treated with crizotinib and re-biopsied at progression showed ALK amplification in 13%, ALK mutations in 31%, and KRAS or EGFR pathway activation in 31%; 19% patients had HSP90, KIT, or HER2 activation (46).